Sapanisertib

Generic Name: Sapanisertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅N_₇O

CAS Number: 1224844-38-5

Unique Ingredient Identifier: JGH0DF1U03

Background: Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Fibrolamellar Carcinoma
Ovarian Carcinoma
Pancreatic Neuroendocrine Tumor
Advanced Malignant Solid Neoplasm

Interventions: Drug: Sapanisertib
Biological: Ziv-Aflibercept

First Posted Date: 2014-06-10

Last Posted Date: 2024-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 83

Registration Number: NCT02159989

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Recurrent Uterine Corpus Cancer
Solid Neoplasm
Stage IIIB Fallopian Tube Cancer AJCC v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Ovarian Endometrioid Adenocarcinoma
Ovarian Clear Cell Cystadenocarcinoma
Ovarian Mucinous Cystadenocarcinoma
Ovarian Serous Cystadenocarcinoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2014-05-20

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT02142803

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Phase 1

Terminated

Conditions: Glioblastoma
Gliosarcoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2014-05-07

Last Posted Date: 2024-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT02133183

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy